Antares Pharma has reported revenues of $3.12m for the third quarter ended 30 September 2010, an increase of 89%, compared to $1.66m for the same period in 2009.
Antares Pharma has posted a net loss of $1.63m for the third quarter 2010, or $0.02 loss per diluted share, compared to net loss of $2.82m, or $0.04 loss per diluted share, for the comparable period in 2009.
Antares Pharma’s operating loss was $1.67m, compared to $2.54m for the comparable period in 2009.
The company has posted a revenue of $9.54m, for the nine months ended 30 September 2010, compared to $5.73m for the year ago period.
For the nine months ended 30 September 2010, the company has posted a net loss of $4.79m, or $0.06 loss per diluted share, compared to $7.88m, or $0.11 loss per diluted share, for the year ago period.
Operating loss for the nine months ended 30 September 2010 was $4.8m, compared to $7.21m for the year ago period.
Antares Pharma president and CEO Paul Wotton said that the quality revenues and strong results of the third quarter demonstrate that since their product focused strategic plan was put into place eighteen months ago, they have not only stabilised the Company, but have also entered into a new growth phase.
“Increased product revenue and continued advancement of our pipeline programs, including the epinephrine auto injector, Vibex MTX and Anturol, provide a solid foundation for future growth,” Wotton said.